Verily, an Alphabet precision health technology company, and OneOncology, the national platform for independent oncology practices, have established a strategic partnership that will enable more efficient clinical trials.
As part of the agreement, Verily will integrate its clinical trial management software (CTMS) platform, SignalPath, across practices in the OneOncology Research Network, OneR. SignalPath will enable sites to improve their systems infrastructure, streamline regulatory processes, and enhance collaboration with sponsors.
“Clinical trial research is core to high-quality cancer care programs,” said Dr. Davey Daniel, Chief Medical Officer, OneOncology. “By using technology to create a platform offering from OneR, we can help enhance our partners’ clinical trial programs, which ultimately better democratizes clinical trials, and improves health equity.”
SignalPath is the only CTMS that uses next-generation protocol digitization technology to configure and systematize study protocol workflows within the platform, saving site staff time and effort. It’s designed to improve the costs, complexities, and time associated with running clinical studies while optimizing for quality and time with patients.
“Verily and OneOncology are both committed to transforming the experience for oncology practices participating in research with the latest data and technology,” said Dr. Brad Hirsch, Head of Product & Implementation at Verily and co-founder of SignalPath. “SignalPath delivers on that vision, easing the workflow for oncologists and their staff, so they can focus on delivering the best possible care.”
This partnership aims to expand research opportunities across community oncology centers, offering the potential to increase access and participation in clinical trials for new cancer treatments. There are over 1,300 anticancer drugs in the development pipeline, but the participation rate in trials among adult cancer patients in the U.S. is only 6%.
OneOncology will continue to partner with Verily as it further develops connected solutions across its research and care product offerings, including an oncology-focused longitudinal registry to advance cancer research.